Insulet Corporation (PODD) - NASDAQ
  • Thu, Apr. 28, 4:26 PM
    • Insulet (NASDAQ:PODD): Q1 EPS of -$0.19 in-line.
    • Revenue of $81.2M (+32.6% Y/Y) beats by $2.04M.
    • Shares +1.2%.
    • Press Release
    | Thu, Apr. 28, 4:26 PM | 5 Comments
  • Nov. 5, 2015, 5:07 PM
    • Insulet (NASDAQ:PODD): Q3 EPS of -$0.33 misses by $0.07.
    • Revenue of $87.3M (+16.4% Y/Y) beats by $3.75M.
    • Shares +8.5% AH.
    | Nov. 5, 2015, 5:07 PM
  • Apr. 30, 2015, 5:40 PM
    | Apr. 30, 2015, 5:40 PM
  • Mar. 5, 2015, 1:06 PM
    • Ultra thinly-traded nano cap Capricor Therapeutics (OTCQB:CAPR +40.2%) jumps on modest turnover of 37K shares in response to its announcement that patient enrollment is underway for its Phase 2 dose-ranging study of Cenderitide, a dual receptor natriuretic peptide agonist for the treatment of heart failure in the outpatient setting.
    • The trial will enroll 14 patients with stable chronic heart failure. Patients will receive up to eight consecutive days of Cenderitide through subcutaneous infusion using Insulet's (PODD +2%) drug delivery system based on the technology in its OmniPod insulin pump. The study will assess the safety, tolerability, pharmacokinetics and pharmacodynamic response to increasing levels of open-label Cenderitide. Each patient will receive the entire range of doses.
    • Cenderitide is designed to be delivered as an outpatient therapy via subcutaneous infusion for up to 90 days.
    • According to the American Heart Association, heart failure is the leading cause of hospitalization among patients at least 65 years of age, accounting for over 1M admissions per year. Approximately 24% are re-hospitalized within one month and 50% within six months. The Affordable Care Act may not allow Medicare reimbursement for heart failure readmissions within 30 days so there is a significant need for outpatient-based therapies that will assist patients from returning to the hospital.
    | Mar. 5, 2015, 1:06 PM | 1 Comment
  • Jan. 15, 2015, 12:45 PM
    | Jan. 15, 2015, 12:45 PM
  • Jan. 15, 2015, 10:01 AM
    • Insulet (PODD -24.8%) plummets on double normal volume in early trading. Yesterday's presentation at JPM15 apparently failed to excite investors. JP Morgan, Raymond James and Sterne Agee all downgraded the stock to a neutral rating.
    | Jan. 15, 2015, 10:01 AM | 2 Comments
  • Jan. 15, 2015, 9:16 AM
    | Jan. 15, 2015, 9:16 AM | 9 Comments
  • Jan. 8, 2015, 12:47 PM
    | Jan. 8, 2015, 12:47 PM | 1 Comment
  • Jan. 7, 2015, 5:35 PM
    | Jan. 7, 2015, 5:35 PM
  • Sep. 27, 2013, 1:57 PM
    • DexCom (DXCM -8.2%) sinks after the FDA approves Medtronic's (MDT +0.2%) MiniMed 530G.
    • Billed as an "artificial pancreas," the device shuts down insulin delivery when it senses blood sugar levels have fallen too low.
    • Both DXCM and Insulet (PODD -2.6%) could have done without the news — the companies market glucose monitors and insulin pumps.
    | Sep. 27, 2013, 1:57 PM
  • Jul. 18, 2013, 11:56 AM
    Insulet (PODD -1.2%) slips on a downgrade to Underperform at Northland Securities.
    | Jul. 18, 2013, 11:56 AM
  • May 7, 2013, 12:52 PM
    Midday top 10 gainers: FSGI +28%. ARCI +27%. ININ +18%. MELI +18%. NLS +18%. PRTS +18%. REED +16%. PODD +14%. LAS +12%. MKTG +12%.
    Midday top 10 losers: DCO -27%. RKUS -25%. GNK -24%. CUTR -23%. ARUN -22%. SNTA -15%. AMRI -12%. PIKE -12%. TA -12%. PTRY -11%.
    | May 7, 2013, 12:52 PM
  • May 7, 2013, 10:33 AM

    Insulet (PODD +10.6%) gets lifted today after its Q1 easily beat estimates. Revenue and gross profit increased by over 20% Y/Y, boosted by strong demand for its new OmniPod Insulin Pump. For the full year 2013, the company reiterates its revenue view of $240M to $255M, above the Street view of $248.4M.

    | May 7, 2013, 10:33 AM
  • May 6, 2013, 4:30 PM
    Insulet (PODD): Q1 EPS of -$0.20 beats by $0.01. Revenue of $57.4M (+20% Y/Y) beats by $0.14M. Shares +5.2% AH. (PR)
    | May 6, 2013, 4:30 PM
  • Nov. 9, 2012, 4:06 PM

    Insulet (PODD +6.2%) finishes strong despite posting a mixed Q3 report yesterday. Revenue grew by 22% Y/Y, and investors are focusing on it's pipeline, which includes its OmniPod insulin pump currently awaiting FDA approval. Barrington thinks approval should come within 90 days. The firm expects the stock to outperform its peers once it's granted and reiterates an Outperform rating on the stock.

    | Nov. 9, 2012, 4:06 PM
  • Feb. 13, 2012, 1:51 PM
    Insulet (PODD +2.7%), a maker of insulin infusion devices for diabetics, is trading higher thanks to a bullish note from Barrington. While noting Insulet's recent Q4 report missed estimates, the firm still expects Insulet's OmniPod pump to act as a positive catalyst for shares.
    | Feb. 13, 2012, 1:51 PM
Company Description
Insulet Corp. engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. Through its OmniPod Insulin Management System, the company seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes.... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States